Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-04-02
2010-11-09
Landau, Sharmila Gollamudi (Department: 1611)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266220
Reexamination Certificate
active
07829573
ABSTRACT:
The invention concerns the use of a combination of an anti-angiogenic agent and an anti-hypertensive agent for use in the manufacture of a medicament for the treatment of a disease state associated with angiogenesis in a warm-blooded mammal, such as a human being. The invention also relates to pharmaceutical compositions comprising an anti-angiogenic agent and an anti-hypertensive agent, to kits thereof and to a method of treatment of a disease state associated with angiogenesis which comprises the administration of an effective amount of a combination of an anti-angiogenic agent and an anti-hypertensive agent to a warm-blooded animal, such as a human being.
REFERENCES:
patent: 5350751 (1994-09-01), Wagner et al.
patent: 5440046 (1995-08-01), Wagner et al.
patent: 5646136 (1997-07-01), Petrow et al.
patent: 6191144 (2001-02-01), Isner
patent: 6455283 (2002-09-01), Ferrara et al.
patent: 7074800 (2006-07-01), Stokes et al.
patent: 7166625 (2007-01-01), Egan et al.
patent: 2003/0191055 (2003-10-01), Epstein et al.
patent: 2005/0043395 (2005-02-01), Wedge
patent: 2005/0222183 (2005-10-01), Wedge
patent: 2005/0245549 (2005-11-01), Wedge
patent: 2006/0009418 (2006-01-01), Barge
patent: 2006/0142316 (2006-06-01), Wedge et al.
patent: 2006/0160775 (2006-07-01), Wedge
patent: 2006/0167024 (2006-07-01), Wedge
patent: 2006/0167027 (2006-07-01), Wedge et al.
patent: 2006/0223815 (2006-10-01), Curwen et al.
patent: 2007/0135462 (2007-06-01), Wedge
patent: 2008/0015205 (2008-01-01), Wedge
patent: 2008/0113039 (2008-05-01), Wedge
patent: 2008/0119479 (2008-05-01), Wedge
patent: 2008/0125447 (2008-05-01), Wedge
patent: 2008/0200436 (2008-08-01), Wedge
patent: 2008/0269261 (2008-10-01), Wedge et al.
patent: 2008/0306094 (2008-12-01), Wedge
patent: 2009/0123474 (2009-05-01), Blakey et al.
patent: 2009/0176731 (2009-07-01), Wedge
patent: WO 97/30035 (1997-08-01), None
patent: WO 98/28006 (1998-07-01), None
patent: WO 00/13703 (2000-03-01), None
patent: 00/47212 (2000-08-01), None
patent: WO 01/32651 (2001-10-01), None
patent: WO 03/039551 (2003-05-01), None
patent: WO 2004/014383 (2004-02-01), None
patent: WO 2004/014426 (2004-02-01), None
patent: WO 2004/032937 (2004-04-01), None
patent: WO 2004/071397 (2004-08-01), None
patent: WO 2004/098604 (2004-11-01), None
patent: WO 2005/004870 (2005-01-01), None
patent: WO 2005/004871 (2005-01-01), None
patent: WO 2005/004872 (2005-01-01), None
patent: WO 2005/092303 (2005-10-01), None
patent: WO 2005/092384 (2005-10-01), None
patent: WO 2005/092385 (2005-10-01), None
patent: WO 2006/035203 (2006-04-01), None
patent: WO 2006/035204 (2006-04-01), None
patent: WO 2006/048633 (2006-05-01), None
patent: WO 2007/003933 (2007-01-01), None
patent: WO 2007/068895 (2007-06-01), None
patent: WO 2007/071958 (2007-06-01), None
patent: WO 2007/071970 (2007-06-01), None
patent: WO 2008/037996 (2008-04-01), None
patent: WO 2008/125820 (2008-10-01), None
Hardman, J. G., Editor-in-Chief, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, Chapter 33, Antihypertnesive Agents and the Drug Therapy of Hypertension, pp. 780-805, 1996.
Ku., D. D. et al., American Physiological Society, H586-H591, 1993.
Horowitz et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Arteriosclerosis, thrombosis, and Vascular Biology. 1997;17:2793-2800, electronic copy, pp. 1-16.
Edwards et al. Transport of [3H]Losartan across isolated perfused rabbit proximal tubule. The Journal of Pharmacology and Experimental Therapeutics. 1999; 290 (No. 1): 38-42.
Landzberg et al. (Landzberg et al. Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures. Progress in Cardiovascular Diseases. 1997; vol. XXXIX, No. 4: 361-398.
Kaplan. Angiotensin II receptor antagonists in the treatment of hypertension. American Family Physician. 1999;60:1185-1190, electronic pp. 1-7.
Hennequin et al. (J. Med. Chem. 1999, 42(26), 5369-5389).
“Acidic and Basic FGFs Dilate Arterioles of Skeletal Muscle Through a NO-Dependent Mechanism” by H. Mac Wu et al., Amer. Physiological Soc., 1996.
“Nitric Oxide Mediates Mitogenic Effect of VEGF on Coronary Venular Endothelium” by Morbidelli et al., Amer. Physiological Society, 1996.
“Cardiovascular Effects of Basic Fibroblast Growth Factor in Rats” by Boussairi et al., Journal of Cardiovascular Pharmacology, 1994.
“Effects of Vascular Endothelial Growth Factor on Hemodynamics and Cardiac Performance” by Yang et al., Journal of Cardiovascular Pharmacology, 1996.
“Role of Vascular Endothelial Cell Growth Factor in Ovarian Hyperstimulation Syndrome” by Levin et al., Journal of Clinical Investigation, vol. 102, No. 11, Dec. 19998.
“Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients with Advanced Cancer”, by Gordon et al., Journal of Clinical Oncology, vol. 19, No. 3, Feb. 1, 2001.
“Vascular Endothelial Growth Factor Induces EDRF-dependent Relaxation in Coronary Arteries” by David D. Ku et al., American Physiological Society, 1993.
Karamsetty et al, 2001,Jnl. Pharmacol. and Experimental Therapeutics, vol. 297, No. 3, pp. 968-974.
Levitzki, A. and Gazit, A. “Tyrosine Kinase Inhibition: An Approach to Drug Development”,Science267 (5205): 1782-1788, 1995.
Li, J.S., Knaf O. L., Turgeon A. et. al. “Effect of Endothelin Antagonism on Blood Pressure and Vascular Structure in Renovascular hypertensive rats”Am. Jnl. Physiol. Heart Circ. Physiol. 271: H88-H93, 1996.
Lopez, J.J., Laham, R.J., Carrozza, J.P et. al. (1997) Haemodynamic Effects of Intracoronary VEGF Delivery : Evidence of Tachyphylaxis and NO Dependence of Response,Am. J. Physiol. 273, H1317-H1323.
Nestel et al, 1999,Jnl. Clin. Endocrinology&Metabolism, vol. 84, No. 5, pp. 895-898.
Rivas et al, 2002,Jnl. of Nutrition, 132, pp. 1900-1902.
Curwen Jon Owen
Ogilvie Donald James
AstraZeneca AB
Klinkel Kortney L
Landau Sharmila Gollamudi
Morgan & Lewis & Bockius, LLP
LandOfFree
Therapeutic combinations of antihypertensive and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic combinations of antihypertensive and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic combinations of antihypertensive and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4243547